AI-designed drugs reach late-stage trials: GB-0895, ENV-294 in Phase IIa, rentosertib recruiting Phase III
FinanceYF5 · x · 2026-10-09
AI-assisted drug discovery is entering late-stage clinical development: Generate Biomedicines' GB-0895 and Enveda's ENV-294 (for eczema and asthma) are in Phase IIa, while Insilico Medicine's rentosertib is recruiting for Phase III trials.
This marks AI-designed molecules moving en masse into human validation, and upcoming trial results will determine whether they are truly safe and effective—a key test for the AI pharma paradigm.
Related event: AI-Designed Drugs Advance into Late-Stage Clinical Trials(2 posts)→
More from Apps
- A 10-Prompt Chain to Fully Optimize Your LinkedIn Profile with AI — anthara_ai · 2026-10-09
- Therapist runs paid therapy sessions inside viral Lagos Life game, paid to real bank account — omojumiller · 2026-10-09
- Gamma, at 100M+ users, rebuilds and relaunches roughly every 3 months — FinanceYF5 · 2026-10-09
- User slams AI assistant Dots for forgetting tasks; says Grok Bot is far better — koltregaskes · 2026-10-09
- Stop using AI like a stranger: ground it in your Obsidian notes and projects — dSebastien · 2026-10-09
- Apogee: dev rebuilds Mozilla's killed Orbit AI tool as a local, privacy-first open-source app — zxdc7896 · 2026-10-09